desmethyl tegoprazan

Desmethyl tegoprazan is the principal *active metabolite* of tegoprazan, a novel potassium-competitive acid blocker (P-CAB) used primarily for acid-related gastrointestinal disorders. Desmethyl tegoprazan forms via hepatic metabolism of tegoprazan, most likely through CYP3A4-mediated N-demethylation of the parent drug. Although chemically similar, desmethyl tegoprazan possesses one less methyl group on the benzimidazole nitrogen compared to the parent compound. Its pharmacological activity mimics that of tegoprazan, reversibly and competitively inhibiting the gastric H+/K+-ATPase (proton pump) in parietal cells and thereby suppressing gastric acid secretion. The clinical efficacy and safety data for tegoprazan principally reflect the parent drug, with the metabolite contributing to its acid-suppressing effects[1].

Other names

M1 metabolite of tegoprazanM-1 metabolite of tegoprazanM 1 metabolite of tegoprazantegoprazan M1